MSDC-0160 and MSDC-0602 are first in class insulin sensitizers called mTOT Modulators and are being developed to treat patients diagnosed with non-alcoholic fatty liver disease (including NASH), polycystic kidney disease, type 2 diabetes, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.


MSDC-0160 successfully completed a Phase 2a clinical trial at Rush University Medical Center (Chicago) in patients diagnosed with mild dementia due to Alzheimer’s disease. The study was funded by the Alzheimer’s Drug Discovery Foundation. MSDC-0160 is also being studied in preclinical models of Parkinson’s disease, in collaboration with researchers at Van Andel Institute (Grand Rapids, Michigan), A 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose Phase 2b clinical study in 258 patients with type 2 diabetes was completed in December 2011. Data from this study was published in Clinical Pharmacology & Therapeutics (advance online publication 6 March 2013).


MSDC-0602 has been evaluated in animal models of fatty liver disease supported by a grant from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health. MSDC-0602 has also being investigated in preclinical models of polycystic kidney disease in preclinical animal models in collaboration with researchers at PreClinomics and the Mayo Clinic. A 28-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose Phase 2a study in 129 patients with type 2 diabetes completed in August 2011. This proof-of-concept clinical study showed that MSDC-0602 achieved significant glucose control and increased insulin sensitivity in type 2 diabetes patients.


MSDC is utilizing traditional medicinal chemistry to develop new chemical entities (NCEs) that are non-TZD, oral mTOT Modulator insulin sensitizers for the treatment of type 2 diabetes.